[
  {"id":"B02-20160301-001","en":"ANDS (Abbreviated New Drug Submission)","fr":"ANDS (Présentation abrégée de drogue nouvelle)"},
  {"id":"B02-20160301-031","en":"EU NDS (Extraordinary Use New Drug Submission)","fr":"EU NDS (Présentation de drogue nouvelle pour usage exceptionnel)"},
  {"id":"B02-20160301-032","en":"EUSNDS (Extraordinary Use Supplement to a New Drug Submission)","fr":"EUSNDS (Supplément à une présentation de drogue nouvelle pour usage exceptionnel)"},
  {"id":"B02-20160301-038","en":"Level 3 – Notice of Change","fr":"Level 3 – Notice of Change"},
  {"id":"B02-20160301-046","en":"MPNC (Pre-Submission Meeting Information)","fr":"MPNC (Réunion préalable - PM)"},
  {"id":"B02-20160301-047","en":"MPNDS (Pre-Submission Meeting Information)","fr":"MPNDS (Réunion préalable – PDN)"},
  {"id":"B02-20160301-049","en":"MPSNDS (Pre-Submission Meeting Information)","fr":"MPSNDS (Réunion préalable – RPPDN)"},
  {"id":"B02-20160301-050","en":"NC (Notifiable Change)","fr":"NC (Préavis de modification)"},
  {"id":"B02-20160301-051","en":"NDS (New Drug Submission)","fr":"NDS (Présentation de drogue nouvelle)"},
  {"id":"B02-20160301-067","en":"PAND (Pandemic Application)","fr":"PAND (Demande pandémique)"},
  {"id":"B02-20160301-068","en":"PBRER-C (Periodic Benefit Risk Evaluation Report - Confirmatory)","fr":"PBRER-C"},
  {"id":"B02-20160301-069","en":"PBRER-PV (Periodic Benefit Risk Evaluation Report - Post-market Vigiliance)","fr":"fr_PBRER-PV (Periodic Benefit Risk Evaluation Report - Post-market Vigiliance)"},
  {"id":"B02-20160301-075","en":"PRNDS (Request for Priority Review Status: NDS)","fr":"PRNDS (Demande de statut d’évaluation prioritaire - PDN)"},
  {"id":"B02-20160301-077","en":"PRSNDS (Request for Priority Review Status: SNDS)","fr":"PRSNDS (Demande de statut d’évaluation prioritaire - SPDN)"},
  {"id":"B02-20160301-078","en":"PSUR-C (Periodic Safety Update Report - Confirmatory)","fr":"PSUR-C (Rapport périodique de pharmacovigilance - Confirmation)"},
  {"id":"B02-20160301-079","en":"PSUR-PV (Periodic Safety Update Report - Post-Market Vigilance)","fr":"PSUR-PV (Rapport périodique de pharmacovigilance - pharmacovigilance)"},
  {"id":"B02-20160301-080","en":"RMP-PV (Risk Management Plan - Post-Market Vigilance)","fr":"RMP-PV (Plan de gestion des risques - Pharmacovigilance)"},
  {"id":"B02-20160301-082","en":"SANDS (Supplement to an Abbreviated New Drug Submission)","fr":"SANDS (Supplément à une présentation abrégée de drogue nouvelle)"},
  {"id":"B02-20160301-084","en":"SNDS (Supplement to a New Drug Submission)","fr":"SNDS (Supplément à une présentation de drogue nouvelle)"},
  {"id":"B02-20160301-085","en":"SNDS-C (Supplement to a New Drug Submission - Confirmatory)","fr":"SNDS-C (Supplément à 'une présentation de drogue nouvelle - Confirmation)"},
  {"id":"B02-20160301-087","en":"UD-PV (Undefined Data Post-market Vigilance)","fr":"UD-PV (Données non définies – Pharmacovigilance)"},
  {"id":"B02-20160301-088","en":"UDRA (Undefined Regulatory Activity)","fr":"UDRA (Activité réglementaire non définie)"},
  {"id":"B02-20160301-089","en":"YBPR (Yearly Biologic Product Report)","fr":"YBPR (Rapport annuel sur un produit biologique)"},
  {"id":"B02-20160301-028","en":"DSUR (Developmental Safety Update Report)","fr":"fr_DSUR (Developmental Safety Update Report)"},
  {"id":"B02-20160301-018","en":"DINA (Application for Drug Identification Number)","fr":"fr_DINA (Application for Drug Identification Number)"},
  {"id":"B02-20160301-019","en":"DINB (Application for Drug Identification Number - Biologic)","fr":"fr_DINB (Application for Drug Identification Number - Biologic)"},
  {"id":"B02-20160301-020","en":"DIND (Application for Drug Identification Number - Disinfectant Product)","fr":"fr_DIND (Application for Drug Identification Number - Disinfectant Product)"},
  {"id":"B02-20160301-021","en":"DINF (Application for Drug Identification Number - Category IV Product)","fr":"fr_DINF (Application for Drug Identification Number - Category IV Product)"},
  {"id":"B02-20160301-043","en":"MPDIN (Pre-Submission Meeting Information)","fr":"fr_MPDIN (Pre-Submission Meeting Information)"},
  {"id":"B02-20160301-070","en":"PDC (Post-Authorization Division 1 Change)","fr":"PDC (Post-Authorization Division 1 Change)"},
  {"id":"B02-20160301-071","en":"PDC-B (Post-Authorization Division 1 Change - Biologics)","fr":"fr_PDC-B (Post-Authorization Division 1 Change - Biologics)"}
]

